Menu
No results found.
PYC
PYC Therapeutics Limited – ASX
Weekly Share Price & Valuation Overview
Market Overview
Open
1.3000
Close
1.2600
High
1.3150
Low
1.2400
Trend
0.42452
PYC Therapeutics Limited
Australia
• ASX - Australian Securities Exchange
• PYC
• Currency: AUD
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
Potential weaknesses
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares. Revenue estimated from Revenue/share × Shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- AUD 769.90M
- Enterprise Value Operating value: market cap + total debt − cash.
- AUD 568.14M
- Total Revenue (TTM) Estimated Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- AUD 33.25M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- AUD 24.99M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- AUD 0.06
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.11
- Shares Outstanding
- 583.26M
- Float Shares
- 278.47M
- Implied Shares Outstanding
- 583.26M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. EBITDA suppressed where implausible vs revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-2.25%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
75.16%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-1.93%
- ROA Return on assets: net income ÷ total assets.
-
-58.01%
- ROE Return on equity: net income ÷ shareholder equity.
-
-1.13%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Strong Year-over-year revenue growth.
-
32.90%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 5.41
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.02
- Total Cash Cash and equivalents.
- AUD 49.25M
- Total Debt Short + long-term interest-bearing debt.
- AUD 1.21M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- AUD -48.04M
Cash Flow
Shown only when internally consistent; margins are TTM.
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- AUD -48.77M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- AUD -31.67M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-146.68%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-95.25%
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 3
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 1
Operational quality/consistency (0–3, higher is better).
Composite Score: 2
Overall internal composite (0–3, higher is better).
Suggested Allocation: 3.33%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
47.7%
Insiders
Shares held by company insiders (officers, directors).
45.4%
Institutions
Shares held by institutions (funds, pensions).
2.4%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
None detected
Net Debt
Total debt − cash (negative = net cash).
AUD -48.04M
-144.5% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
100
Methodology Notes
- Total Revenue (TTM) estimated from Revenue per Share × Shares due to feed inconsistency.
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 10:05
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.